Cost consequences of different diagnostic strategies and different treatment targets for women with gestational diabetes

Project Code: 10459245

Faculty: Liggins Institute

Department: Liggins Institute

Main Supervisor: Professor Caroline Crowther

Application open date: 15 Jan 2020

Application deadline: 30 Jun 2021

Enrolment information: NZ Citizens, NZ Permanent Residents, International

Introduction

Gestational diabetes mellitus (GDM) is a major health problem globally. Within New Zealand one in every 11 pregnant women or over 5,500 women annually are affected. There is global controversy as to the precise degree of glucose intolerance required for the diagnosis of GDM, leading to the use of several different diagnostic criteria worldwide. Similarly there is controversy as to the optimal glycaemic targets to use for women with gestational diabetes.

 

The GEMS Trial is assessing the effects of the new IADPSG criteria compared with current recommended New Zealand criteria on maternal and infant health outcomes.

 

The TARGET Trial has assessed the use of tight with less tight treatment targets for women with gestational diabetes on maternal and infant health.

 

This research project will compare health care utilisation between the two diagnostic criteria used in the GEMS Trial and also the two treatment targets used in the TARGET Trial.

What we are looking for in a successful applicant

Background in a health discipline with an interest in health economics or an economics background. Examples include (but are not limited to) health economics, public health, epidemiology, medicine and midwifery. Knowledge of the New Zealand health care system is required.

Objective

To establish the cost effectiveness of the new IADPSG criteria for the diagnosis of GDM, compared with current recommended New Zealand criteria.

To establish the cost effectiveness of the use of tighter treatment targets with less tight treatment targets for women with GDM.

Related opportunities